The TRIPS agreement provides protection to trade secrets. Elucidate.

The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement), administered by the World Trade Organization (WTO), provides for the protection of trade secrets under Article 39 . While TRIPS does not explicitly define 'trade secret', it refers to them as 'undisclosed information' and sets out the conditions under which such information must be protected by member countries. Key Provisions of TRIPS Article 39 for Trade Secret Protection: Definition of Undisclosed Information: Article 39.2 mandates that natural and legal persons shall have the possibility of preventing information lawfully in their control from being disclosed to, acquired by, or used by others without their consent in a manner contrary to honest commercial practices. For information to qualify for this protection, it must meet three criteria: It is secret in the sense that it is not, as a body or in the precise configuration and assembly of its components, generally known among or readily accessible to persons within the circles that normally deal with that kind of information. It has commercial value because it is secret. It has been subject to reasonable steps under the circumstances, by the person lawfully in control of the information, to keep it secret. Manner Contrary to Honest Commercial Practices: Article 39.2 clarifies what constitutes a "manner contrary to honest commercial practices." This includes, at a minimum, practices such as: Breach of contract. Breach of confidence. Inducement to breach. The acquisition of undisclosed information by third parties who knew, or were grossly negligent in failing to know, that such practices were involved in the acquisition. This provision ensures that trade secrets are protected against unfair acquisition and use, even if they are not formally registered like patents or trademarks. No Requirement for Property Status: The TRIPS Agreement does not require undisclosed information to be treated as a form of property. Instead, it focuses on providing a means to prevent unauthorized disclosure or use, thereby protecting the commercial interests of the holder. Protection of Undisclosed Test Data: Article 39.3 specifically addresses undisclosed test or other data submitted to governments or governmental agencies as a condition for approving the marketing of pharmaceutical or agricultural chemical products which utilize new chemical entities. Member governments are required to protect such data against unfair commercial use. Additionally, they must protect the data against disclosure, except where necessary to protect the public or unless steps are taken to ensure that the data are protected against unfair commercial use. This is particularly important for pharmaceutical companies that invest heavily in clinical trials and data generation. In summary, the TRIPS Agreement provides a framework for the protection of trade secrets by requiring member countries to ensure that undisclosed commercially valuable information, kept secret through reasonable efforts, is protected against acquisition, disclosure, or use in ways that are contrary to honest commercial practices. This protection is crucial for fostering innovation and fair competition by safeguarding valuable business information that does not fall under other forms of IP protection.